Prelude Therapeutics Incorporated
PRLD
$1.34
-$0.01-0.37%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -18.72% | 10.71% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -16.39% | -6.97% | |||
| Operating Income | 36.58% | 6.97% | |||
| Income Before Tax | 36.84% | 2.66% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 36.84% | 2.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 36.84% | 2.66% | |||
| EBIT | 36.58% | 6.97% | |||
| EBITDA | 37.05% | 7.05% | |||
| EPS Basic | 36.96% | 2.65% | |||
| Normalized Basic EPS | 36.98% | 2.65% | |||
| EPS Diluted | 36.96% | 2.65% | |||
| Normalized Diluted EPS | 36.98% | 2.65% | |||
| Average Basic Shares Outstanding | 0.18% | 0.01% | |||
| Average Diluted Shares Outstanding | 0.18% | 0.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||